[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346234-105":59,"doc-detail-346234-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","inhibition-of-gpx4-induces-the-death-of-p53-mutant-triple-negative-breast-cancer-cells","Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells","","Triple-negative breast cancer (TNBC) is an aggressive subtype marked by frequent TP53 mutations and a shortage of effective targeted therapies, making direct mutant p53 targeting difficult. Integrated in vitro and in silico screening identified small molecules that preferentially kill TP53-mutant cells. The ferroptosis inducer ML-162 was tested in vitro and in vivo to define the mechanism of cell death.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/inhibition-of-gpx4-induces-the-death-of-p53-mutant-triple-negative-breast-cancer-cells/346234/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/inhibition-of-gpx4-induces-the-death-of-p53-mutant-triple-negative-breast-cancer-cells/346234.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are TP53-mutant TNBC cells considered hard to target directly?","Question",{"text":112,"@type":113},"TP53 mutations have been difficult to target directly, and only limited mutant-p53 drugs have reached late-stage clinical evaluation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What screening approach was used to find drugs preferentially affecting TP53-mutant cells?",{"text":117,"@type":113},"An integrated screen of small molecules with known protein targets was used to identify compounds that induced preferential death or growth suppression in TP53-mutant cells.",{"name":119,"@type":110,"acceptedAnswer":120},"How does ML-162 affect TP53-mutant TNBC cells and what is its key mechanism?",{"text":121,"@type":113},"ML-162 induces preferential ferroptosis in TP53-mutant TNBC cells, and in vivo treatment suppresses tumor growth while increasing lipid peroxidation; GPX4 inhibition or knockout enhances ferroptosis in TP53-missense mutants.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346234,1790167718,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Breast Cancer Research and Treatment (2026) 215:49 [https://doi.org/10.1007/s10549-025-07865-6](https://doi.org/10.1007/s10549-025-07865-6)  \nInhibition of GPX4 induces the death of p53‑mutant triple‑negative breast cancer cells  \nWilliam M. Tahaney1,2 · Amanda Lanier2 · Jing Qian2 · Cassandra L. Moyer2 · Nghi Nguyen3 · Yanxia Ma2 · Jamal Hill2 · Reid T. Powell3 · Clifford C. Stephan3 · Peter J. A. Davies3 · Abhijit Mazumdar2 · Powel H. Brown1,2  \nReceived: 6 August 2024 / Accepted: 16 November 2025 / Published online: 6 January 2026 © The Author(s) 2025  \nAbstract  \nBackground Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high rates of tumor protein 53 (TP53) mutation and with limited targeted therapies. Despite being clinically advantageous, direct targeting of mutant TP53 has been challenging. Therefore, we hypothesized that p53-mutant TNBC cells rely upon other potentially targetable survival pathways.  \nMethods In vitro and in silico screens were used to identify drugs that induced preferential death in TP53-mutant cells. The effect of the ferroptosis inducer ML-162 was tested both in vitro and in vivo and the mechanism of cell death following ML-162 treatment or GPX4 knockout was determined.  \nResults High-throughput drug screening demonstrated that TP53-mutant TNBCs are highly sensitive to peroxidase, cell cycle, cell division, and proteasome inhibitors. We further characterized the effect of the ferroptosis inducer ML-162 and demonstrated that ML-162 induces preferential ferroptosis in TP53-mutant TNBC cells. Treatment of TP53-mutant xenografts with ML-162 suppressed tumor growth and increased lipid peroxidation in vivo. Testing ferroptosis inducers demonstrated TP53-missense mutant, and not TP53-null or wild-type cells, were more sensitive to ferroptosis, and expression of mutant TP53 genes in p53-null cells sensitized cells to ML-162 treatment.  \nConclusions This study demonstrates that TP53-mutant TNBC cells have unique survival pathways that can be effectively targeted. Our results illustrate the intrinsic vulnerability of TP53-mutant TNBCs to ferroptosis and highlight GPX4 as a potential target for the precision treatment of TP53-mutant TNBC.  \nKeywords TNBC · p53 · TP53 · GPX4 · Ferroptosis · Gain-of-function  \nAbbreviations  \n4-HNEALOX15  \nAUC  \nCCLE  \nER  \nFS-1  \n4-Hydroxynonenal Arachidonate 15-Lipoxygenase Area Under the Curve Cancer Cell Line Encyclopedia Estrogen Receptor Ferrostatin-1  \n* Powel H. Brown [phbrown@mdanderson.org](phbrown@mdanderson.org)  \n1 Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA  \n2 Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA  \n3 Center for Translational Cancer Research, Institute of Biosciences and Technology, Texas A&M University, Houston, TX, USA  \nGPX4  \nHER2  \nLH  \nLO  \nLOH  \nLOOH  \nMETABRIC  \nNec-1  \np53, TP53 PANTHER  \nPR  \nSTR  \nTCGA  \nTNBC  \nZ-VAD  \nGlutathione Peroxidase 4  \nHuman Epidermal Growth Factor Receptor 2  \nLipid  \nLipid Radical  \nLipid Alcohol  \nLipid Hydroperoxide  \nMolecular Taxonomy of Breast Cancer International Consortium Necrostatin-1  \nTumor Protein 53  \nProtein Analysis Through Evolutionary Relationships  \nProgesterone Receptor  \nShort Tandem Repeat The Cancer Genome Atlas Triple-Negative Breast Cancer Z-VAD(OMe)-FMK  \nBackground  \nTriple-negative breast cancer (TNBC) represents 15–20% of all breast cancer diagnoses, has a poor prognosis, and is treated predominantly with chemotherapy [1, 2] . Though TNBCs exhibit a wide range of mutations, one defining feature is the high frequency of mutations in the Tumor Protein 53 gene (TP53), reported between 80 and 90%[3] . The p53 protein plays crucial roles in the control of signals balancing cellular growth, survival, and death [4, 5]. However, in the presence of TP53 mutations, cells lose the tumor suppressive functions of p53 and can gain oncog","cbCaibt1dvvFoWnS","https://ap.wps.com/l/cbCaibt1dvvFoWnS","pdf",2556213,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n## Clinical context and rationale\n## Integrated screening strategy\n# Methods\n## Dataset","[{\"question\":\"Why are TP53-mutant TNBC cells considered hard to target directly?\",\"answer\":\"TP53 mutations have been difficult to target directly, and only limited mutant-p53 drugs have reached late-stage clinical evaluation.\"},{\"question\":\"What screening approach was used to find drugs preferentially affecting TP53-mutant cells?\",\"answer\":\"An integrated screen of small molecules with known protein targets was used to identify compounds that induced preferential death or growth suppression in TP53-mutant cells.\"},{\"question\":\"How does ML-162 affect TP53-mutant TNBC cells and what is its key mechanism?\",\"answer\":\"ML-162 induces preferential ferroptosis in TP53-mutant TNBC cells, and in vivo treatment suppresses tumor growth while increasing lipid peroxidation; GPX4 inhibition or knockout enhances ferroptosis in TP53-missense mutants.\"}]","Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells | PDF",1790060569,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f3cb53148dd72fd7e8ddca2ca6262d81.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aab4a018202f22ebdd808760b963040a.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c81f63d6664f58021be916741db37c7a.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0cd60e627b39819ec67b9d388461d95d.webp",980,1301]